English Abstract
Journal Article
Review
Add like
Add dislike
Add to saved papers

[Neonatal alloimmune thrombocytopenia].

Neonatal alloimmune thrombocytopenia (NAIT) is induced by maternal antibodies directed against fetal platelet alloantigens. Platelet alloantigens involved in NAIT has been documented in HPA-1 (a,b), -2a, -3(a,b), 4(a,b), -5(a,b) and the low frequency alloantigens (Tu/Ca, Mo, Sra,...). Alloimmunization to platelet antigens occurs in 0.94% of pregnant Japanese women. The frequency of NAIT is estimated at 1:3300 births. Incompatibility for HPA-4 is the major (80%) cause of NAIT, followed by HPA-3a (15%) in this population. HPA-5b induced NAIT is rare, despite that the antibody is found often (0.7%) in pregnant women. Since, about half of the cases of NAIT occur during the first pregnancy, it is impossible to anticipate intracranial hemorrhage in many instances. Mild, asymptomatic cases often requires no specific therapy. Compatible platelets irradiated to prevent post-transfusion graft-vs-host disease should be transfused to any infants with severe hemorrhage and can help to prevent bleeding in asymptomatic infants. The administration of intravenous immunoglobulin in NAIT fetus/newborns or pregnant women is worthy of trial.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app